These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [The relationship between tumor necrosis factor-alpha gene promoter polymorphism and obstructive sleep apnea-hypopnea syndrome].
    Author: Liu HG, Guan P, Lin M, Xu YJ, Zhang ZX.
    Journal: Zhonghua Jie He He Hu Xi Za Zhi; 2006 Sep; 29(9):596-9. PubMed ID: 17129465.
    Abstract:
    OBJECTIVE: To investigate the relationship between tumor necrosis factor-alpha (TNF-alpha) gene promoter polymorphism and obstructive sleep apnea-hypopnea syndrome (OSAHS). METHODS: The plasma TNF-alpha level of OSAHS group and non-OSAHS group was detected by enzyme-linked immunosorbent assay (ELISA). Eighteen patients with severe OSAHS were treated with continuous positive airway pressure (CPAP) for 1 month, and the serum levels of TNF-alpha was also measured. The genotypes of TNF-alpha gene promoter polymorphism were determined by polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP). The genotypes and allele of the polymorphisms were compared between OSAHS group and non-OSAHS group. The effects of the polymorphisms in OSAHS group on body mass index (BMI), neck circumference (NC), waist/hip rate (WHR), polysomnography (PSG), systolic blood pressure (SBP), diastolic blood pressure (DBP) were analyzed. RESULTS: The plasma level of TNF-alpha in OSAHS group was higher than the control group [(12.3 +/- 3.62) ng/L and (8.59 +/- 1.62) ng/L, respectively, t = 7.716, P < 0.01]. CPAP significantly decreased the serum levels of TNF-alpha, but its level (10.31 +/- 1.91) ng/L was still higher in the patients than the control group. The frequencies of TNF-alpha AA/AG genotype in OSAHS group (frequencies 31/76, 40.8%) was higher than the control one (frequencies 7/42, 16.7%) (chi(2) = 7.485, P < 0.05). Statistical analysis showed that OSAHS group had a significantly higher TNF-alphaA allele frequency (frequencies 39/152, 25.7%) than that of the control one (frequencies 39/152, 9.5%) (chi(2) = 8.830, P < 0.01). The OSAHS patients with AA/AG genotype had significantly higher serum levels of TNF-alpha, NC, WHR and aphea-hypopnea index [(13.39 +/- 3.71) ng/L, (45.2 +/- 4.2) cm, (0.91 +/- 0.12), and (34.8 +/- 15.6)/h, respectively] than those with GG genotype group [(11.09 +/- 3.54) ng/L, (42.7 +/- 4.9) cm, (0.85 +/- 0.12) and (26.4 +/- 12.3)/h, respectively] (t = 2.725, 2.278, 2.150, 2.609 respectively, P < 0.05 or < 0.01). The L SaO(2) (the lowest SaO(2)) in patients with AA/AG genotype [(78.8 +/- 10.9)%] was significantly lower than that in patients with GG genotype [(83.4 +/- 8.6)%] (t = 2.039, P < 0.05). There was no significant difference in BMI, SBP and DBP. CONCLUSION: The presence of the TNF-alphaA allele may be associated with susceptibility to OSAHS, and it maybe an important candidate gene for OSAHS.
    [Abstract] [Full Text] [Related] [New Search]